<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40394619</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1465-993X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>Respiratory research</Title><ISOAbbreviation>Respir Res</ISOAbbreviation></Journal><ArticleTitle>Lung lipids associated with smoking and ECIG use in a cross-sectional study and clinical trial.</ArticleTitle><Pagination><StartPage>193</StartPage><MedlinePgn>193</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12931-025-03267-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While electronic cigarettes (ECIG) may have lower toxicant delivery than cigarettes, ECIG-liquids and aerosols still contain toxicants that can potentially disrupt lung lipid homeostasis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants from two studies underwent bronchoscopy and bronchoalveolar lavage (BAL). Ninety-eight participants (21-44 years old) were included in a cross-sectional study, with 17 ECIG users, 52 non-smokers, and 29 smokers. In the four-week clinical trial, 30 non-smokers were randomly assigned to use nicotine-free, flavorless ECIG or no use. A panel of 75 quantifiable lipid species and 7 lipid classes were assessed in the BAL using two tandem mass spectrometry (MS/MS) platforms. Ten cytokines and lipid-laden macrophages (LLM) were analyzed using the V-PLEX Plus Proinflam Combo 10 panel and Oil Red O staining, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the cross-sectional study, 43 lipids were associated with smoking status at FDR&lt;0.1, including two between ECIG and non-smokers (PC(14:0/18:1) and PC(18:0/14:0)) in pairwise follow-up analyses (Bonferroni-adjusted p&lt;0.017). Associations between lipid species and cotinine, inflammatory markers, including IL-1&#x3b2; and IL-8, and LLM were also identified, as well as differences in lipid classes between smokers and the other groups. Smokers had higher saturated lipids, including ceramide (CER), sphingomyelin (SM), and diacylglycerol (DAG) than that of non-smokers and ECIG users. No significant associations were identified in the 4-week clinical trial.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Smoking was associated with altered lipid levels, as compared to both non-smokers and ECIG users; the majority were downregulated and ECIG effects tend to be smaller in magnitude than smoking effects, although some were different than those in the smokers group. This is a novel study of healthy individuals examining lipidomic differences between smokers, ECIG users, and non-smokers, indicating potential roles of smoking and ECIG-related lipid alterations in pulmonary disease.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The study was approved by The OSU Institutional Review Board (OSU-2015C0088) in accordance with its ethical standards, the Helsinki declaration, and the Belmont Report, and is registered on Clinicaltrials.gov (NCT02596685; 2015-11-04).</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>McElroy</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Song</LastName><ForeName>Min-Ae</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Environmental Health Sciences, College of Public Health, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barr</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Division of Laboratory Sciences, Centers for Disease Control and Prevention, National Center for Environmental Health, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Laboratory Sciences, Centers for Disease Control and Prevention, National Center for Environmental Health, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinnebrew</LastName><ForeName>Garret</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuklenyik</LastName><ForeName>Zsuzsanna</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Laboratory Sciences, Centers for Disease Control and Prevention, National Center for Environmental Health, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusovschi</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Laboratory Sciences, Centers for Disease Control and Prevention, National Center for Environmental Health, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Jon C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Laboratory Sciences, Centers for Disease Control and Prevention, National Center for Environmental Health, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blount</LastName><ForeName>Benjamin C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Division of Laboratory Sciences, Centers for Disease Control and Prevention, National Center for Environmental Health, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>MuChun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, 460 W. 10 th Avenue, 9&#x2009;th Floor, Suite D920, Columbus, OH, 43210-1240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wewers</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, 460 W. 10 th Avenue, 9&#x2009;th Floor, Suite D920, Columbus, OH, 43210-1240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamel</LastName><ForeName>Sahar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, 460 W. 10 th Avenue, 9&#x2009;th Floor, Suite D920, Columbus, OH, 43210-1240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisinger</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, 460 W. 10 th Avenue, 9&#x2009;th Floor, Suite D920, Columbus, OH, 43210-1240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Amarnath</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, 460 W. 10 th Avenue, 9&#x2009;th Floor, Suite D920, Columbus, OH, 43210-1240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Daniel Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, 460 W. 10 th Avenue, 9&#x2009;th Floor, Suite D920, Columbus, OH, 43210-1240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shields</LastName><ForeName>Peter G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, 460 W. 10 th Avenue, 9&#x2009;th Floor, Suite D920, Columbus, OH, 43210-1240, USA. Peter.Shields@osumc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02596685</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016058</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50CA180908</GrantID><Agency>Center for Tobacco Products</Agency><Country/></Grant><Grant><GrantID>UL1TR001070</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Res</MedlineTA><NlmUniqueID>101090633</NlmUniqueID><ISSNLinking>1465-9921</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electronic Cigarette</Keyword><Keyword MajorTopicYN="N">Lipidomics</Keyword><Keyword MajorTopicYN="N">Smoking</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study was approved by The OSU Institutional Review Board (OSU-2015 C0088) and is registered on Clinicaltrials.gov (NCT02596685). Informed consent was obtained from all participants. Consent for publication: Not Applicable Competing interests: P.G. Shields has provided expert testimony for law firms representing plaintiffs in tobacco litigation. No potential conflicts of interest were disclosed by the remaining co-authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40394619</ArticleId><ArticleId IdType="doi">10.1186/s12931-025-03267-w</ArticleId><ArticleId IdType="pii">10.1186/s12931-025-03267-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Health, N. C. for C. D. P. and H. P. (US) O. on S. and. The Health Consequences of Smoking&#x2014;50 Years of Progress. 1&#x2013;36 (2014).</Citation></Reference><Reference><Citation>Akiyama Y, Sherwood N. Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. Toxicology Reports. 2021;8:282&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxrep.2021.01.014</ArticleId><ArticleId IdType="pubmed">33552927</ArticleId><ArticleId IdType="pmc">7850959</ArticleId></ArticleIdList></Reference><Reference><Citation>Marczylo T. How bad are e-cigarettes? What can we learn from animal exposure models? Journal of Physiology. 2020;598:5073&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP278366</ArticleId><ArticleId IdType="pubmed">32500527</ArticleId></ArticleIdList></Reference><Reference><Citation>Keith R, Bhatnagar A. Cardiorespiratory and Immunologic Effects of Electronic Cigarettes. Current Addiction Reports. 2021;8:336&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40429-021-00359-7</ArticleId><ArticleId IdType="pubmed">33717828</ArticleId><ArticleId IdType="pmc">7935224</ArticleId></ArticleIdList></Reference><Reference><Citation>PG, S. et al. A Review of Pulmonary Toxicity of Electronic Cigarettes in the Context of Smoking: A Focus on Inflammation. Cancer Epidemiol. Biomarkers Prev. 26, 1175&#x2013;1191 (2017).</Citation></Reference><Reference><Citation>Song M-A, et al. Biomarkers of Exposure and Effect in the Lungs of Smokers, Nonsmokers, and Electronic Cigarette Users. Cancer Epidemiol Prev Biomarkers. 2020;29:443&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-19-1245</ArticleId></ArticleIdList></Reference><Reference><Citation>PG, S. et al. Lipid laden macrophages and electronic cigarettes in healthy adults. EBioMedicine 60, (2020).</Citation></Reference><Reference><Citation>MA, S. et al. Effects of Electronic Cigarette Constituents on the Human Lung: A Pilot Clinical Trial. Cancer Prev. Res. (Phila). 13, 145&#x2013;151 (2020).</Citation></Reference><Reference><Citation>M, T. et al. Electronic versus Combustible Cigarette Effects on Inflammasome Component Release into Human Lung. Am. J. Respir. Crit. Care Med. 199, 922&#x2013;925 (2019).</Citation></Reference><Reference><Citation>A, G. et al. Chronic E-Cigarette Use Increases Neutrophil Elastase and Matrix Metalloprotease Levels in the Lung. Am. J. Respir. Crit. Care Med. 200, 1392&#x2013;1401 (2019).</Citation></Reference><Reference><Citation>B, R. et al. E-Cigarette Use Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation and Altered Mucin Secretion. Am. J. Respir. Crit. Care Med. 197, 492&#x2013;501 (2018).</Citation></Reference><Reference><Citation>MC, M. et al. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. J. Clin. Invest. 129, 4290&#x2013;4304 (2019).</Citation></Reference><Reference><Citation>Agudelo, C. W., Samaha, G. &amp; Garcia-Arcos, I. Alveolar lipids in pulmonary disease. A review. Lipids Heal. Dis. 2020 191 19, 1&#x2013;21 (2020).</Citation></Reference><Reference><Citation>MB, F. &amp; RS, S. Surfactant Lipids at the Host-Environment Interface. Metabolic Sensors, Suppressors, and Effectors of Inflammatory Lung Disease. Am. J. Respir. Cell Mol. Biol. 54, 624&#x2013;635 (2016).</Citation></Reference><Reference><Citation>Agudelo, C. W. et al. Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD). PLoS One 15, (2020).</Citation></Reference><Reference><Citation>N, M., GS, S., KK, K. &amp; AS, N. Lipid mediators and asthma: Scope of therapeutics. Biochem. Pharmacol. 179, (2020).</Citation></Reference><Reference><Citation>L, X. et al. Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis. Lipids Health Dis. 17, (2018).</Citation></Reference><Reference><Citation>Lesko, J. et al. Phospholipid dynamics in ex vivo lung cancer and normal lung explants. Exp. Mol. Med. 2021 531 53, 81&#x2013;90 (2021).</Citation></Reference><Reference><Citation>Jain, R. B. &amp; Ducatman, A. Associations between smoking and lipid/lipoprotein concentrations among US adults aged &#x2265;20 years. J. Circ. Biomarkers 7, (2018).</Citation></Reference><Reference><Citation>S, M. et al. Lipid profiles in users of combustible and electronic cigarettes. Vasc. Med. (2021) https://doi.org/10.1177/1358863X211009313 .</Citation></Reference><Reference><Citation>Meenakshisundaram, R., Rajendiran, C. &amp; Thirumalaikolundusubramanian, P. Lipid and lipoprotein profiles among middle aged male smokers: a study from southern India. Tob. Induc. Dis. 8, 11 (2010).</Citation></Reference><Reference><Citation>LK, G. et al. Smoking intensity and lipoprotein abnormalities in active smokers. J. Clin. Lipidol. 3, 372&#x2013;378 (2009).</Citation></Reference><Reference><Citation>Middlekauff, H. R. et al. Changes in lipid composition associated with electronic cigarette use. J. Transl. Med. 2020 181 18, 1&#x2013;10 (2020).</Citation></Reference><Reference><Citation>Kim T, Choi H, Kang J, Kim J. Association between electronic cigarette use and metabolic syndrome in the Korean general population: A nationwide population-based study. PLoS One. 2020;15: e0237983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0237983</ArticleId><ArticleId IdType="pubmed">32822397</ArticleId><ArticleId IdType="pmc">7442237</ArticleId></ArticleIdList></Reference><Reference><Citation>M, J. et al. A systematic survey of lipids across mouse tissues. Am. J. Physiol. Endocrinol. Metab. 306, (2014).</Citation></Reference><Reference><Citation>Song, M. A. et al. Accelerated epigenetic age, inflammation, and gene expression in lung: comparisons of smokers and vapers with non-smokers. Clin. Epigenetics 15, (2023).</Citation></Reference><Reference><Citation>NHIS - Adult Tobacco Use - Glossary. https://archive.cdc.gov/www_cdc_gov/nchs/nhis/tobacco/tobacco_glossary.htm .</Citation></Reference><Reference><Citation>Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, (2019).</Citation></Reference><Reference><Citation>Harris PA, et al. Research electronic data capture (REDCap)&#x2013;a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Song MA, et al. Effects of electronic cigarette constituents on the human lung: A pilot clinical trial. Cancer Prev Res. 2020;13:145&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1940-6207.CAPR-19-0400</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo JL, Hallberg TK. Recurrent aspiration in children: Lipid-laden alveolar macrophage quantitation. Pediatr Pulmonol. 1987;3:86&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.1950030209</ArticleId><ArticleId IdType="pubmed">3588061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazachkov MY, Muhlebach MS, Livasy CA, Noah TL. Lipid-laden macrophage index and inflammation in bronchoalveolar lavage fluids in children. Eur Respir J. 2001;18:790&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003/erj.18.5.790</ArticleId><ArticleId IdType="pubmed">11757629</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner MS, et al. Simultaneous Quantification of Free Cholesterol, Cholesteryl Esters, and Triglycerides without Ester Hydrolysis by UHPLC Separation and In-Source Collision Induced Dissociation Coupled MS/MS. J Am Soc Mass Spectrom. 2017;28:2319&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13361-017-1756-2</ArticleId><ArticleId IdType="pubmed">28801822</ArticleId><ArticleId IdType="pmc">5645443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner MS, et al. Development and application of a high throughput one-pot extraction protocol for quantitative LC-MS/MS analysis of phospholipids in serum and lipoprotein fractions in normolipidemic and dyslipidemic subjects. J Chromatogr B. 2019;1118&#x2013;1119:137&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2019.04.041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y59-099</ArticleId><ArticleId IdType="pubmed">13671378</ArticleId></ArticleIdList></Reference><Reference><Citation>Su B, et al. A DMS Shotgun Lipidomics Workflow Application to Facilitate High-Throughput, Comprehensive Lipidomics. J Am Soc Mass Spectrom. 2021;32:2655&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jasms.1c00203</ArticleId><ArticleId IdType="pubmed">34637296</ArticleId><ArticleId IdType="pmc">8985811</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. (2020).</Citation></Reference><Reference><Citation>Lafleur, B. et al. Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. Journal of Carcinogenesis vol. 10 (2011).</Citation></Reference><Reference><Citation>Therneau, T. A Package for Survival Analysis in R. R package version 3.2-7. (2020).</Citation></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B. 1995;57:289&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland, j. M. &amp; Altman, D. G. Multiple significance tests: The Bonferroni method. BMJ 310, 170 (1995).</Citation></Reference><Reference><Citation>Molenaar MR, et al. LION/web: A web-based ontology enrichment tool for lipidomic data analysis. Gigascience. 2019;8:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giz061</ArticleId></ArticleIdList></Reference><Reference><Citation>PG, S. et al. Lipid laden macrophages and electronic cigarettes in healthy adults. EBioMedicine 60, (2020).</Citation></Reference><Reference><Citation>Wright JR, Clements JA. Metabolism and turnover of lung surfactant. Am Rev Respir Dis. 1987;136:426&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/136.2.426</ArticleId><ArticleId IdType="pubmed">3304047</ArticleId></ArticleIdList></Reference><Reference><Citation>Agassandian M, Mallampalli RK. Surfactant phospholipid metabolism. Biochim Biophys Acta. 2013;1831:612&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2012.09.010</ArticleId><ArticleId IdType="pubmed">23026158</ArticleId></ArticleIdList></Reference><Reference><Citation>Madison MC, et al. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. J Clin Invest. 2019;129:4290&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI128531</ArticleId><ArticleId IdType="pubmed">31483291</ArticleId><ArticleId IdType="pmc">6763255</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, R. de F., Andrade, L. N. de S., Bustos, S. O. &amp; Chammas, R. Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells. Front. Immunol. 13, 768606 (2022).</Citation></Reference><Reference><Citation>Jeong S, et al. Lysophosphatidylcholine Alleviates Acute Lung Injury by Regulating Neutrophil Motility and Neutrophil Extracellular Trap Formation. Front Cell Dev Biol. 2022;10: 941914.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.941914</ArticleId><ArticleId IdType="pubmed">35859904</ArticleId><ArticleId IdType="pmc">9289271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Lysophosphatidylcholine inhibits lung cancer cell proliferation by regulating fatty acid metabolism enzyme long-chain acyl-coenzyme A synthase 5. Clin Transl Med. 2023;13: e1180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.1180</ArticleId><ArticleId IdType="pubmed">36639836</ArticleId><ArticleId IdType="pmc">9839868</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Olefsky JM. INFLAMMATION AND LIPID SIGNALING IN THE ETIOLOGY OF INSULIN RESISTANCE. Cell Metab. 2012;15:635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.04.001</ArticleId><ArticleId IdType="pubmed">22560216</ArticleId><ArticleId IdType="pmc">4156155</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler LM, et al. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.07.013</ArticleId><ArticleId IdType="pubmed">32711004</ArticleId><ArticleId IdType="pmc">7736102</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo Y, et al. CXCL8/IL-8 and CXCL12/SDF-1&#x3b1; Co-operatively Promote Invasiveness and Angiogenesis in Pancreatic Cancer. Int J Cancer. 2009;124:853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.24040</ArticleId><ArticleId IdType="pubmed">19035451</ArticleId><ArticleId IdType="pmc">2684108</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu S, et al. Significance of Oil-Red-O positive macrophages in bronchoalveolar lavage in diagnosing E-cigarettes or vaping product use-associated lung injury: A case series. Diagn Cytopathol. 2021;49:876&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dc.24760</ArticleId><ArticleId IdType="pubmed">33900686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekberg-Jansson A, et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL CO and to emphysematous changes on high resolution CT. RESPIR MED. 2001;95:363&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/rmed.2001.1050</ArticleId><ArticleId IdType="pubmed">11392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon, E. B., Chih-Hsin Yang, J. &amp; Dubinett, S. M. The Role of Interleukin 1&#x3b2; in the Pathogenesis of Lung Cancer. JTO Clin. Res. reports 1, (2020).</Citation></Reference><Reference><Citation>Lewis, A. M., Varghese, S., Xu, H. &amp; Alexander, H. R. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med. 4, (2006).</Citation></Reference><Reference><Citation>Ridker PM, et al. Effect of interleukin-1&#x3b2; inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017;390:1833&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32247-X</ArticleId><ArticleId IdType="pubmed">28855077</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. Lung Defense through IL-8 Carries a Cost of Chronic Lung Remodeling and Impaired Function. Am J Respir Cell Mol Biol. 2018;59:557&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2018-0007OC</ArticleId><ArticleId IdType="pubmed">29894204</ArticleId><ArticleId IdType="pmc">6236688</ArticleId></ArticleIdList></Reference><Reference><Citation>Blount BC, et al. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N Engl J Med. 2020;382:697&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916433</ArticleId><ArticleId IdType="pubmed">31860793</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields, P. G. et al. Lipid laden macrophages and electronic cigarettes in healthy adults. EBioMedicine 60, (2020).</Citation></Reference><Reference><Citation>Phase Transition Temperatures for Glycerophospholipids | Avanti Research. https://avantiresearch.com/tech-support/physical-properties/phase-transition-temps .</Citation></Reference><Reference><Citation>Kelley, E. G., Frewein, M. P. K., Czakkel, O. &amp; Nagao, M. Nanoscale Bending Dynamics in Mixed-Chain Lipid Membranes. Symmetry 2023, Vol. 15, Page 191 15, 191 (2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>